Core Viewpoint - WuXi AppTec's subsidiary, WuXi Biologics, has seen its stock price rise significantly following the announcement of its CAR-T product, Beinuoda, being included in the first version of the National Healthcare Security Administration's commercial health insurance innovative drug list [1] Group 1: Company Developments - WuXi Biologics' stock price increased by over 9% in early trading, currently up 7.79% at HKD 3.32, with a trading volume of HKD 2.6756 million [1] - The company announced that its first domestically developed CAR-T product, Beinuoda (Rikioranase injection), has been successfully included in the innovative drug list by the National Healthcare Security Administration [1] Group 2: Product Information - Beinuoda is currently the only CAR-T product in China approved for three non-Hodgkin lymphoma indications, including relapsed/refractory large B-cell lymphoma, relapsed/refractory follicular lymphoma, and relapsed/refractory mantle cell lymphoma [1] - Prior to its inclusion in the national commercial insurance innovative drug list, Beinuoda had already been recognized for its significant clinical value, being included in over 100 universal insurance plans and nearly 100 million medical insurance plans, demonstrating extensive clinical practice and real-world research validation among Chinese patients [1]
药明巨诺-B早盘涨超9% 倍诺达 获纳入国家医保局商保创新药目录